SynthesisHeart failure reviews2015
The short-term and long-term effects of tolvaptan in patients with heart failure: a meta-analysis of randomized controlled trials.
Synthesis in Heart failure reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 7 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Evaluating the safety and effectiveness of tolvaptan in patients with heart failure and renal impairment: a systematic review and meta-analysis.European journal of clinical pharmacology · 2025Pooled it
- Tolvaptan for water retention in heart failure: a systematic review.Systematic reviews · 2023Pooled it
- The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis.ESC heart failure · 2021Pooled it
- Pooled it
- Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis.BMC cardiovascular disorders · 2017Pooled it
- The Efficacy and Safety of Tolvaptan in Patients with Hyponatremia: A Meta-Analysis of Randomized Controlled Trials.Clinical drug investigation · 2017Pooled it
- Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis.PloS one · 2017Pooled it
- Follicular metabolic dysfunction, oocyte aneuploidy and ovarian aging: a review.Journal of ovarian research · 2025Review
- Prognostic effect of a vasopressin VEuropean journal of clinical pharmacology · 2024Article
- The management of acute and chronic hyponatraemia.Therapeutic advances in endocrinology and metabolism · 2022Review
- Renoprotection by long-term low-dose tolvaptan in patients with heart failure and hyponatremia.ESC heart failure · 2021Article
- Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure.Internal medicine (Tokyo, Japan) · 2019Review
- Correction of Hyponatremia May Be a Treatment Stratification Biomarker: A Two-Stage Systematic Review and Meta-Analysis.Journal of clinical medicine · 2018Article
- Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure.Cardiology research · 2017Review
- Risk factors for hypernatremia in patients with short- and long-term tolvaptan treatment.European journal of clinical pharmacology · 2016Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A comprehensive evaluation of the benefits of tolvaptan for the management of heart failure (HF) is lacking. The objective of this meta-analysis was to assess the short-term and long-term effects of tolvaptan in patients with HF. Articles were searched from PubMed, MEDLINE and Cochrane Library before March 31, 2015. Randomized controlled trials enrolling adult HF patients and reporting the all-cause mortality, cardiac events, body weight change or changes of serum electrolytes including sodium, potassium and creatinine were included in our meta-analysis. Ten studies covering 5574 patients met the inclusion criteria. Based on the data of meta-analysis, tolvaptan had no impact on the all-cause mortality [relative risk (RR) 0.96; 95 % confidence interval (CI) 0.87-1.06; P = 0.40] and incidence of cardiac events (RR 1.03; 95 % CI 0.96-1.11; P = 0.40) of HF patients. Furthermore, in comparison with control treatments, tolvaptan significantly decreased the body weight [weight mean difference (WMD), -0.87; 95 % CI -1.03 to -0.71; P < 0.001] and statistically increased serum sodium (WMD, 2.58; 95 % CI -1.83 to 3.33; P < 0.001) without any change in serum potassium (WMD, 0.01; 95 % CI -0.03 to 0.05; P = 0.577). However, serum creatinine may be increased slightly by tolvaptan (WMD, 0.05; 95 % CI 0.03-0.07; P < 0.001). This meta-analysis suggests that in HF patients, tolvaptan may not bring long-term benefits, but it effectively improves the volume overload and hyponatremia without obvious increases in serum potassium and creatinine. Hence, tolvaptan is likely to be a promising diuretic for the treatment of HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.